COMMON STI571: A COST-EFFECTIVE ALTERNATIVE?

The introduction of common imatinib represents a significant chance for patients battling chronic myeloid leukemia and other conditions. Original brand-name imatinib, often referred to as Gleevec, carries a considerable price cost, frequently causing accessibility for some individuals. Generic ve